The 18-Month MDR-TB Regimen Has a Successor - Takeaway - MDSpire
Commentary & Perspectives

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.

Share

  • 1

    NHS England saw pretomanid prescriptions rise from 9 to 45 patients/month.

  • 2

    Shorter regimens are being adopted for MDR-TB.

  • 3

    Evidence supports favorable outcomes for newer treatments.

  • 4

    Expert oversight and funding pathways ensure safe implementation.

  • 5

    Monitoring guidance is crucial to minimize toxicity risks.

  • 6

    Treatments are accessible to vulnerable populations.

  • 7

    UK model can offer insights on managing MDR-TB effectively.

Original Source(s)

The 18-Month MDR-TB Regimen Has a Successor

  • by Kerri Miller

  • April 16, 2026

Related Content

Temple Lung Center: Advances in Lung Care and Research in 2025

Pulmonary care is evolving rapidly, from earlier detection strategies to new minimally invasive therapies and expanding access to clinical trials.

  • by

  • April 13, 2026

  • 1 min
Sex Does Not Modify Asthma Attack Predictors

Prior attacks predict risk more strongly in male patients, while type 2 biomarkers perform similarly across sexes

Flu Vaccination Linked to Lower Heart, Stroke Risk After Infection

A Danish registry study suggests prior influenza vaccination is associated with lower short-term cardiovascular risk following breakthrough infection.